Journal of Cardiovascular Disease Research
Assess the safety and efficacy of amitriptyline, pregabalin, and gabapentin for the management of neuropathic pain at Ayaan Institute of Medical Sciences
Dr Kamal Hasan .K, Dr Gnana Deepthi Koppolu
JCDR. 2024: 3276-3284
Abstract
Background: The most prevalent neuropathic pain disorders now being treated with tricyclic antidepressants (TCA), gabapentin, and pregabalin are considered first-line treatments for neuropathic pain. Many times, current neuropathic pain treatments are ineffective. Despite the availability of substantial information from numerous recommendations, there is still a significant degree of heterogeneity in treatment patterns. According to recent statistics from the Indian market, the guidelines actually advocate the use (selling) of medications including amitriptyline, pregabalin, and gabapentin.
» PDF